RELATED BLOG POSTS:
Crospovidone and Microcrystalline Cellulose: A Novel Description of Pharmaceutical Fillers in the Gastrointestinal Tract.
0 CommentsAm J Surg Pathol. 2017 Apr;41(4):564-569. doi: 10.1097/PAS.0000000000000790. Shaddy SM1, Arnold MA, Shilo K, Frankel WL, Harzman AE, Stanich PP, Singhi AD, Yearsley MM, Arnold CA. Author information 1…
Read MoreDifference in the Dissolution Behaviors of Tablets Containing Polyvinylpolypyrrolidone (PVPP) Depending on Pharmaceutical Formulation After Storage Under High Temperature and Humid Conditions.
0 CommentsJ Pharm Pharm Sci. 2016 Oct - Dec;19(4):511-519. doi: 10.18433/J3HW3Q. Takekuma Y1, Ishizaka H, Sumi M, Sato Y, Sugawara M. Author information 1 Faculty of…
Read MoreA pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation.
0 CommentsDrug Deliv Transl Res. 2017 Jun;7(3):450-459. doi: 10.1007/s13346-017-0367-6. Moutasim MY1, ElMeshad AN2, El-Nabarawi MA2. Author information 1 Department of Pharmaceutics and Industrial Pharmacy,…
Read MoreEvaluation of disintegrants functionality for orodispersible mini tablets.
0 CommentsDrug Dev Ind Pharm. 2017 Nov;43(11):1770-1779. doi: 10.1080/03639045.2017.1339081. Epub 2017 Jun 21. Soulairol I1,2, Chaheen M1,3, Tarlier N1, Aubert A1, Bataille B1, Sharkawi T1. Author information…
Read MoreFormulation strategy towards minimizing viscosity mediated negative food effect on disintegration and dissolution of immediate release tablets.
0 CommentsFormulation strategy towards minimizing viscosity mediated negative food effect on disintegration and dissolution of immediate release tablets. Zaheer K1, Langguth P1. Author…
Read MoreDesign and Evaluation of Bilayer Pump Tablet of Flurbiprofen Solid Dispersion for Zero-Order Controlled Delivery.
0 CommentsDesign and Evaluation of Bilayer Pump Tablet of Flurbiprofen Solid Dispersion for Zero-Order Controlled Delivery. Cheng L1, Li T1, Dong L1, Wang X1, Huo Q1, Wang H1, Jiang…
Read MoreThe Impact of Amorphisation and Spheronization Techniques on the Improved in Vitro & in Vivo Performance of Glimepiride Tablets.
0 CommentsMakar RR1, Latif R2, Hosni EA3, El Gazayerly ON2. Author information Adv Pharm Bull. 2017 Dec;7(4):557-567. doi: 10.15171/apb.2017.067. Epub 2017 Dec 31. Abstract Purpose: Triple…
Read MoreDevelopment and analytical characterization of a new antiparasitic fenbendazole compound tablet and pharmacokinetic investigations after its oral administration to dogs.
0 CommentsAbstract The objective of this study was to prepare a new compound fenbendazole tablet containing 29.7 % fenbendazole, 1.50 % praziquantel and…
Read MoreTECHNICAL INFORMATION – MENDONYL™ CROSPOVIDONE (PVPP)
MENDONYL™ XL, XL-10.
Almost white free-flowing powder.
They have a slight characteristic odor, and are practically tasteless.
TEST | Mendonyl™ XL | Mendonyl™ XL-10 |
Identification, A B C | Pass | Pass |
Identification D | Type A | Type B |
Solubility (Insoluble in ) | practically insoluble in water | |
PH ( in 1% suspension ) | 5.0 – 8.0 | 5.0 – 8.0 |
Loss on drying | ≦5.0% | ≦5.0% |
Water | ≦5.0% | ≦5.0% |
Water-soluble matter | ≦1.0% | ≦1.0% |
Acid-Alcohol soluble matter | ≦1.0% | ≦1.0% |
Peroxides ( as H2O2 ) | ≦400ppm | ≦400ppm |
Free N-vinylpyrrolidone | ≦10ppm | ≦10ppm |
Residue on ignition | ≦0.1% | ≦0.1% |
Heavy metals | ≦10ppm | ≦10ppm |
Assay, as Nitrogen content | 11.0 – 12.8 | 11.0 – 12.8 |
MENDONYL™ K25, K30, K90
MICROBIOLOGICAL STATUS | MAX 100 Aerobic Plate Count CFU/g | |||
MAX 100 Mold and Yeast CFU/g | ||||
No Escherichia /g | ||||
No Pseudomonas aeruginosa /g | ||||
No Salmonella /10g | ||||
No Staphylococcus aureus /g |
Freely soluble in water and many organic compounds.
Pharmaceutical formulations using PVPP:
Ingredients | mg/tab |
Griseofulvin | 500 |
Povidone (VA 64) | 100 |
Dimethylformamide | 7500 |
Crospovidone | 75 |
Lactose monohydrate | 75 |
Magnesium stearate | 5 |
Colloidal silicon dioxide | 5 |
Ingredients | mg/tab |
Sulfadimidine | 500 |
Lactose monohydrate | 100 |
Povidone (K30) | 15 |
Purified water | 200 |
Crospovidone | 25 |
Talc | 2.4 |
Colloidal silicon dioxide | 0.3 |
Calcium arachinate | 0.3 |
Ingredients | mg/tab |
Captopril | 25 |
Ludipress | 91 |
Crospovidone | 2 |
Magnesium stearate | 2 |
Ingredients | mg/tab |
Mefenamic acid | 250 |
Cornstarch | 30 |
Povidone (90F) | 50 |
Isopropyl alcohol | QS |
Crospovidone | 12 |
Microcrystalline cellulose 101 | 85 |
Magnesium stearate | 5 |
Ingredients | mg/tab |
Probenecid | 500 |
Cornstarch | 130 |
Povidone (K30) | 10 |
Alcohol | 70.00 mL |
Crospovidone | 25 |
Colloidal silicon dioxide | 3 |
Magnesium stearate | 3 |
Ingredients | mg/tab |
Raloxifene HCl | 60 |
Lactose anhydrous | 156 |
Povidone | 7.2 |
Polysorbate 80 | 7.2 |
Crospovidone | 7.2 |
Magnesium stearate | 2.4 |
Ingredients | mg/tab |
Fucidine | 125 |
Dicalcium phosphate (Di-Tab) | 63 |
Povidone (90F) | 2.5 |
Isopropyl alcohol | 30 mL |
Crospovidone | 6.2 |
Colloidal silicon dioxide | 1.3 |
Magnesium stearate | 3 |
Ingredients | mg/tab |
Thiamine mononitrate | 7 |
Riboflavin | 5 |
Nicotinamide | 25 |
Pyridoxine hydrochloride | 20 |
Calcium D-pantothenate | 12 |
Calcium carbonate | 75 |
Calcium glycerophosphate | 164 |
Sodium bicarbonate | 400 |
Tartaric acid (powder) | 300 |
Sucrose | 400 |
Sucrose | 350 |
Povidone (K30) | 50 |
Povidone (K30) | 10 |
Isopropanol | QS |
Ascorbic acid (powder) | 550 |
Riboflavin | 2 |
Cyanocobalamin (gelatin coated, 0.1%) | 5 |
PEG-6000 (powder) | 40 |
Crospovidone | 50 |
(source: handbook of Pharmaceutical Manufacturing Formulations, Compressed Solid Products. Author: Sarfaraz K. Niazi)